Bioinformatics Report - The forecasts and future of the market 2006-2011

Table of Contents

1. Executive Summary: Bioinformatics 2006-2011

2.Introduction - Bioinformatics is A Key Enabling Technology in Drug Development

• 2.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
• 2.2 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
• 2.3 The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
  • 2.3.1 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
• 2.4 The Growing Market for Bioinformatic Products and Services: Where Information Technology Combines with Science & Research
  • 2.4.1 Bioinformatics Is Highly Relevant to Pharmaceutical Development
• 2.5 Bioinformatics Developed As a Consequence of Increasing Requirements for Computational Resources in the Life Sciences
  • 2.5.1 Computational Biology
  • 2.5.2 The Human Genome Project Has Provided Important Scope for the Development and Use of Bioinformatics
  • 2.5.3 Pharmacogenomics is Increasingly Relevant to Pharmaceutical Development
  • 2.5.4 Proteomics Constitutes the "Next Step" After Genomics
• 2.6 Biological Databases
• 2.7 Bioinformatic Tools for Searching and Analysis
  • 2.7.1 Sequence Analysis
  • 2.7.2 Genomic Annotation
  • 2.7.3 Similarity Searching
  • 2.7.4 Analysis of Gene Expression
  • 2.7.5 Analysis of Gene Regulation
  • 2.7.6 Analysis of Mutations in Cancer
  • 2.7.7 Analysis of Protein Expression
  • 2.7.8 Structural Analysis of Proteins
  • 2.7.9 Functional Analysis of Proteins
• 2.8 Other Applications of Bioinformatics with Relevance to Medicine
  • 2.8.1 High-Throughput Image Analysis and Morphometrics
  • 2.8.2 Modelling Biological Systems "In Silico"
• 2.9 Potential Benefits of Using Bioinformatic Tools in the Pharmaceutical Industry

3. Forecast of the Market for Bioinformatics, 2006-2011

• 3.1 Spending on Bioinformatics Will Increase Strongly from 2006-2011
  • 3.1.1 The Race to Make Use of The Human Genome Has Already Started, Resulting In a Large Boost for The Sales of Bioinformatic Products and Services In the Pharmaceutical Sector
  • 3.1.2 Bioinformatics Is An Emerging But Fragmented Industry
  • 3.1.3 New Technologies Lead to An Increasing Demand for Bioinformatic Solutions
  • 3.1.4 To Be Truly Successful, Bioinformatic Technology Providers Need to Understand the Value Chain in Drug Development
• 3.2 The US will Continue to Lead the World in Spending on Bioinformatics
• 3.3 Analytical Software Will Contribute the Highest Proportion of Revenues in the Global Bioinformatics Market
  • 3.3.1 Emerging Bioinformatic Technologies Can Reduce The Time and Costs of Developing Drugs Significantly, But Greater Validation of the Technology is Required
  • 3.3.2 Databases and Related Content Remain An Important Part of the Bioinformatics Market
  • 3.3.3 High-Throughput Screening is Another Key R&D Technology that Serves As a Driver for Sales of Bioinformatic Tools for Data Storage and Analysis
• 3.4 The Share of Bioinformatics Revenues Contributed by Proteomic Applications Will Increase At the Expense of Genomic Applications
  • 3.4.1 Genomics and Proteomics are Closely Linked, With The Profile of the Latter Rising
  • 3.4.2 There is a Need For More Unified, Holistic Solutions in Bioinformatics
  • 3.4.3 Pharmacogenomics Can Potentially Change The Paradigm of Drug Development
  • 3.4.4 The Successful Application of Pharmacogenomics Will Require Regulatory Changes - Some Progress is Evident, But Much Uncertainty Remains
• 3.5 Conclusions from Visiongain's Forecast for the Pharmaceutical Bioinformatics Market

4. A Discussion of Issues Affecting Bioinformatics in Pharmaceutical Applications

• 4.1 A SWOT Analysis for the Bioinformatics Sector With Relevance to Pharmaceutical Development
• 4.2 Bioinformatic Solutions Will Continue To Expand Their Presence in the Pharmaceutical Industry - Further R&D Efficie ncies Are Predicted
• 4.3 Bioinformatic Applications Face No Significant Restraints to Their Continuing Adoption Within the Pharmaceutical Sector
• 4.4 Vast Amounts of Data Remain to Be Processed via Bioinformatics - There is a Need For Holistic Solutions In Particular
• 4.5 Bioinformatics Is Presently A Complex Mix of Public and Private Data Sources
• 4.6 Trends in the Market for Bioinformatic Products and Services with Pharmaceutical Relevance
• 4.7 Bioinformatics Is One of The Most Important Areas of Investment Among The Emerging Technologies
• 4.8 Benefits of Informatics in Drug Discovery & Development Are Real
• 4.9 Developments in Genomics Drive the Bioinformatics Market, With Benefits to the Pharmaceutical Industry Increasing from 2006-2011
• 4.10 Bioinformatics Companies Have To Change Their Commercial Focus If They Are to Succeed
  • 4.10.1 Some Bioinformatics Companies Have Struggled In Recent Years
  • 4.10.2 Leaders In Mainstream IT Provide Extra Competition for Specialised Bioinformatics Companies
  • 4.10.3 Some Drug Discovery Companies Are Moving Into Bioinformatics
• 4.11 There is Still A Perception That Bioinformatic Solutions Are Restricted to Highly Specialised Applications
• 4.12 Recent Trends in the Business Strategies Adopted by Informatic Companies
  • 4.12.1 The Decision to Adapt to Changing Market Demands
  • 4.12.2 Informatics Companies to Span Life Science Market Areas
  • 4.12.3 Changing the Focus from Informatics Services to Tackling Therapeutic Drug R&D Bottlenecks & Content
  • 4.12.4 Expanding Services to Incorporate Drug R&D Processes
• 4.13 The Commercialisation of Informatics in the Pharmaceutical & Biotechnology Industry
  • 4.13.1 Recent Trend from In Vivo Research to In Silico Research
  • 4.13.2 A Shift in Commercial Focus for the Application of Informatics
  • 4.13.3 The Use of Informatics to Transform Genomic Sequence Data into Drug Targets

5. Current Events in Bioinformatics That Are Indicative of the Prevailing Direction of The Sector

• 5.1 Fundamental Issues Affecting the Current Market
  • 5.1.1 Broadening Business Strategy to Span other Life Science Areas
  • 5.1.2 There is Intense Competition in the Bioinformatics Market
  • 5.1.3 Lion Bioscience Sold Its Loss-Making Bioinformatics Unit
• 5.2 The Current Success of the Biotechnological Industry Will Greatly Benefit the Bioinformatics Sector
• 5.3 Broadening Business Strategy to Span other Life Science Areas
• 5.4 Partnerships in the Bioinformatics Sector
  • 5.4.1 There is an Increasing Trend to Outsource, With India Being a Beneficiary
  • 5.4.2 Bioinformatics Partnership Announced by IDBS and In Silico Discovery
  • 5.4.3 Invitrogen Forms Collaboration with Solexa
  • 5.4.4 Sigma-Aldrich Launches Online Tool for Analysing Biological Pathways
  • 5.4.5 Novascreen Launches a Screening Service for Next-Generation Drug Screening
  • 5.4.6 AstraZeneca Is Placing A Great Emphasis on Imaging Technology to Benefit Development
  • 5.4.7 Sigma-Aldrich and Rosetta Inpharmatics Establish Partnership for siRNA Design
  • 5.4.8 Collaboration Between GenoLogics Life Sciences Software and Bioinformatics Solutions Could Provide Important Gains in Proteomics Research
  • 5.4.9 Capgemini wins IT Contract With Eli Lilly
  • 5.4.10 Pfizer harnesses Indian IT and Bioinformatics Strengths
• 5.5 CuraGen Show Marked Innovation In Bioinformatics, Especially the Combining of Functions
• 5.6 Current Developments Will Have A Strong Positive Effect on Bioinformatics, With Benefits to Pharmaceutical R&D

6. Future Developments in Bioinformatics

• 6.1 Responses to Question Submitted to Experts in Industry and Academia Concerning Future Trends in Bioinformatics
  • 6.1.1 Views on the Current State of the Bioinformatics Market
  • 6.1.2 The Issues Needed to be Considered By Pharmaceutical Companies With Regard to Bioinformatics
  • 6.1.3 Will Bioinformatics Significantly Increase Efficiencies in R&D?
  • 6.1.4 What Are The Most Promising Applications in Pharmaceutical R&D?
  • 6.1.5 Will Bioinformatics Become Increasingly Prominent in R&D?
  • 6.1.6 Is Bioinformatics Truly Moving from Gene Discovery to Proteomics?
  • 6.1.7 Will Bioinformatics Impact Upon Clinical Testing?
  • 6.1.8 Will the Validation of Bioinformatic Tools Become Standard Practice?
  • 6.1.9 The Role of Bioinformatics Companies
• 6.2 Academic Institutions Play An Important Role In Developmental Aspects of Bioinformatics
  • 6.2.1 Leading Bioinformatics Groups Worldwide
  • 6.2.2 Wellcome Trust Sanger Institute, UK
  • 6.2.3 The Brutlag Bioinformatics Group - Stanford University, US
  • 6.2.4 The University of Manchester Bioinformatics Group, UK
  • 6.2.5 The European Bioinformatics Institute (EBI), UK
  • 6.2.6 South African National Bioinformatics Institute (SANBI)

7. Conclusions

• 7.1 Bioinformatics and its Applications in the Pharmaceutical Industry
• 7.2 Visiongain Predicts Strong Growth in Revenues for Bioinformatic Services and Products
• 7.3 Analytical Software Will Contribute the Highest Proportion of Revenues in the Global Bioinformatics Market
• 7.4 The Bioinformatics Sector Will Benefit From Strong Driving Forces - Especially The Race To Apply Genomic Data
• 7.5 There Are Some Restraints to the Bioinformatics Sector But These Will Not Have a Particularly Drastic Effect
• 7.6 The Situation for Pharmaceutical Bioinformatics Is Very Positive Overall

Appendices

• Appendix A. Transcripts of Interviews with Key Industry Experts
• Appendix A.1 Interview with Dr Edward Maggio, Chairman & CEO, Structural Bioinformatics
• Appendix A.2 Interview with Dr David Speechly, Vice President of Investor Relations, Applied Biosystems
• Appendix A.3 Interview with Dr George J. Maalouf, President, Genomix Corporation
• Appendix B. About visiongain

List of Tables

• Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
• Table 2.2 Informatic Market Segments Relevant to the Pharmaceutical Industry
• Table 3.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Table 3.2 Total World Spending ($bn) on Drug Discovery, 2005-2011
• Table 3.3 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug Discovery, 2005-2011
• Table 3.4 Market Share (%) and Spending ($m) on Bioinformatics by Geographical Region, 2005 & 2011
• Table 3.5 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011
• Table 3.6 Contributions (%) to World Bioinformatics Spending According to Product/Service Type, 2005 & 2011
• Table 3.7 Contributions ($m) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Table 3.8 Contributions (%) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Table 4.1 A SWOT Chart for the Bioinformatic Applications in the Pharmaceutical Sector, 2006-2011
• Table 4.2 Expenditure of Leading Pharmaceutical Companies on New Technologies, 2005
• Table 4.3 Different Types of Data & Information Analysed by Informatics Techniques
• Table 7.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Table 7.2 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug Discovery, 2005-2011
• Table 7.3 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011

List of Figures

• Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
• Figure 2.2 The Increasing Average Cost ($m) of NME Development, 1976-2005
• Figure 2.3 The Role of Databases in Life Sciences Research
• Figure 2.4 Potential Applications of Informatics in Drug Discovery & Development
• Figure 3.1 Total World Spending ($bn) on Bioinformatics, 2005-2011
• Figure 3.2 Total World Spending ($bn) on Drug Discovery and Bioinformatics Compared, 2005-2011
• Figure 3.3 Spending on Bioinformatics As a Percentage (%) of Total Spending on Drug
• Figure 3.4 Total World Spending ($m) on Bioinformatics by Geographical Region, 2005 and 2011
• Figure 3.5 Total World Spending (%) on Bioinformatics by Geographical Region, 2005
• Figure 3.6 Total World Spending (%) on Bioinformatics by Geographical Region, 2011
• Figure 3.7 A Breakdown of World Bioinformatics Spending ($m) According to Product/Service Type, 2005-2011
• Figure 3.8 A Breakdown of World Bioinformatics Spending (%) According to Product/Service Type, 2005
• Figure 3.9 A Breakdown of World Bioinformatics Spending (%) According to Product/Service Type, 2011
• Figure 3.10 Contributions (%) to World Bioinformatics Spending According to Product/Service Type, 2005 & 2011
• Figure 3.11 Contributions ($m) to World Bioinformatics Spending by Applications for Pharmacogenomics and Protoeomics, 2005-2011
• Figure 3.12 Contributions (%) to World Bioinformatics Spending by Pharmacogenomics and Protoeomics, 2005 & 2011
• Figure 4.1 Expenditure of Leading Pharmaceutical Companies on New Technologies, 2005

List of Organisations

• Accelrys
• Affymetrix
• Agilent
• Applied Biosystems
• Astellas
• AstraZeneca
• AxCell BioSciences
• Beckman Coulter
• BioChem Pharma
• Biodirectory
• BioDiscovery
• Bioinformatics Solutions
• Biomax Informatics
• Bio-Rad
• Capgemini
• Celera Genomics
• Compaq
• Compugen
• Confirmant
• CuraGen
• DiaDexus
• DNAStar
• Double Twist
• DuPont
• Eli Lilly
• Entigen Corporation
• Exelixis
• Fujitsu
• GE Healthcare Bio-Sciences
• Genaissance Pharmaceuticals
• Gene Codes
• GenoLogics Life Sciences Software
• Genomica
• Genomix Corporation
• Google
• Hewlett-Packard
• Hitachi
• Hybrigenics
• IBM
• IDBS
• In Silico Discovery
• Incyte Genomics
• Informax
• Invitrogen
• Johnson & Johnson
• Kirin
• Lion Biosciences
• Media Cybernetics
• Merck & Co
• Millennium Pharmaceuticals
• Motorola
• Myriad Genetics
• NetGenics
• Novartis
• NovaScreen BioSciences
• Novo Nordisk
• OGS
• Oracle
• Pfizer
• Protein Lounge
• Roche Applied Science
• Rosetta Inpharmatics
• Sanofi-Pasteur
• Sigma-Aldrich
• Silicon Genetics
• Solexa
• Spotfire
• Structural Bioinformatics
• Structural Genomix
• Sun Microsystems
• The Boston Consulting Group
• Viaken Systems
• Wyeth
• Yamanouchi